Home » Stocks » VIR

Vir Biotechnology, Inc. (VIR)

Stock Price: $42.15 USD -1.22 (-2.81%)
Updated Jan 21, 2021 1:06 PM EST - Market open
Market Cap 5.52B
Revenue (ttm) 75.61M
Net Income (ttm) -256.79M
Shares Out 125.81M
EPS (ttm) -14.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $42.15
Previous Close $43.37
Change ($) -1.22
Change (%) -2.81%
Day's Open 44.00
Day's Range 40.30 - 44.85
Day's Volume 1,186,941
52-Week Range 16.26 - 60.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Yahoo Finance - 5 days ago

Vir Biotechnology President and CEO explains COVID-19 antibody treatment

#coronavirusvaccine #COVID19vaccine #coronaviruspandemic Vir Biotechnology President and CEO George Scangos discusses antibody treatment and why it is going to be difficult to achieve herd imm...

The Motley Fool - 1 week ago

The biotech announced updates about collaborations with two big partners.

CNBC Television - 1 week ago

Our Covid antibody treatment will work against new strains: Vir CEO

CNBC's Meg Tirrell discusses coronavirus antibody treatments in light of new Covid strains across the world with Vir CEO George Scangos at the J.P. Morgan Healthcare Conference.

GlobeNewsWire - 1 week ago

– First Phase 2 clinical trial to combine immunomodulation and antigen suppression approaches in HBV cure research –

Business Wire - 1 week ago

FOSTER CITY, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clin...

Other stocks mentioned: GILD
GlobeNewsWire - 1 week ago

SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE...

Zacks Investment Research - 4 weeks ago

Investors need to pay close attention to in Vir Biotechnology (VIR) stock based on the movements in the options market lately.

Market Watch - 1 month ago

Shares of Vir Biotechnology Inc. gained 1.3% in premarket trading on Friday, the day after the biotech and GlaxoSmithKline said they started dosing patients in a late-stage clinical trial for ...

Other stocks mentioned: GSK
GlobeNewsWire - 1 month ago

– Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 –

GlobeNewsWire - 1 month ago

SAN FRANCISCO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeffrey Hatfield, an accomplished industry executive with more than th...

Bloomberg Markets and Finance - 1 month ago

Future Vaccines Have 'High Barrier' to Cross, Vir CEO Says

Dec.04 -- Vir Biotechnology Inc. Chief Executive Officer George Scangos says the manufacturing of vaccines is a highly regulated, complex process and the capacity to make drugs for Covid-19 is...

Barrons - 1 month ago

Competitors have already gotten emergency use authorizations from regulators and booked orders for their antibody treatments.

The Motley Fool - 1 month ago

They'll be later to market than rivals. But if their product candidates are stronger, investors may reap rewards.

Other stocks mentioned: VXRT
GlobeNewsWire - 2 months ago

SAN FRANCISCO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, toda...

Seeking Alpha - 2 months ago

Vir Biotechnology has a deep pipeline across many disease segments, reducing concentration risk in the portfolio and expanding commercial reach. The company has key collaborations with large p...

GlobeNewsWire - 2 months ago

– Manuscript highlights the importance of molecular surveillance of SARS-CoV-2 immune evasion and rational design of vaccines and antibody therapies for COVID-19 – – Manuscript highlights the ...

GlobeNewsWire - 2 months ago

SAN FRANCISCO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, toda...

The Motley Fool - 3 months ago

Two small biotechs collaborated to find a coronavirus vaccine, but one of them may come out way ahead due to its expertise and other partnerships.

Other stocks mentioned: ALNY, BIIB, GSK
GlobeNewsWire - 3 months ago

SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that Phil Pang, M.D...

GlobeNewsWire - 3 months ago

SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of preclinical research in an influenza animal model highlighting a new m...

Zacks Investment Research - 3 months ago

Vir Biotechnology (VIR) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.

Benzinga - 3 months ago

Vir Biotechnology Inc (NASDAQ: VIR) shares were rallying Tuesday after the company provided an update on its partnered COVID-19 treatment program. Vir's COVID-19 Antibody Update: Vir said it i...

Other stocks mentioned: GSK
Forbes - 3 months ago

The global trial of the experimental antibody therapy will expand following promising safety results in early trial participants.

Other stocks mentioned: GSK
Investors Business Daily - 3 months ago

Vir Biotechnology and U.K.-based partner GlaxoSmithKline said they are expanding Phase 3, or final-phase, clinical trials for a possible Covid-19 antibody treatment. VIR stock jumped.

Other stocks mentioned: GSK
Market Watch - 3 months ago

Shares of Vir Biotechnology Inc. gained 5.3% in trading on Tuesday after the company said it is expanding the Phase 3 clinical trial for an experimental COVID-19 treatment.

Other stocks mentioned: GSK
24/7 Wall Street - 3 months ago

Vir Biotechnology Inc. (NASDAQ: VIR) shares jumped on Tuesday after the firm announced, in conjunction with GlaxoSmithKline PLC (NYSE: GSK), that they would be expanding their late-stage COVID...

Other stocks mentioned: GSK
CNBC Television - 3 months ago

VIR, GSK begin Phase 3 trial for Covid-19 antibody drug

Vir Biotechnology and GlaskoSmithKline are expanding their coronavirus antibody drug into Phase 3 trials following positive safety and tolerability data in Phase 2. CNBC's Meg Tirrell reports.

Other stocks mentioned: GSK
GlobeNewsWire - 3 months ago

SAN FRANCISCO and LONDON, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the global expansion to Phase 3 of the...

Other stocks mentioned: GSK
Skynews - 3 months ago

The developers of a potential COVID-19 vaccine have moved trials to a third phase, hailing "rapid achievement" to date.

Other stocks mentioned: GSK
The Motley Fool - 3 months ago

Both of these biotechs have promising COVID-19 programs. But one of them appears to have a clear edge.

Other stocks mentioned: BNTX
GlobeNewsWire - 3 months ago

– Largest -to-date analysis of serum samples from nearly  650 SARS-CoV-2-infected patients –

Zacks Investment Research - 3 months ago

Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.

Other stocks mentioned: BNTX, MRNA, NVAX
The Motley Fool - 4 months ago

Investors bid its shares way up this year, but the market just slashed their value.

GlobeNewsWire - 4 months ago

SAN FRANCISCO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, t...

GlobeNewsWire - 4 months ago

SAN FRANCISCO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, t...

GlobeNewsWire - 4 months ago

SAN FRANCISCO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Janet Napolitano to its board of directors. Napolitano brings a bre...

Yahoo Finance - 4 months ago

Coronavirus treatment: Glaxosmithkline partners with Vir to start antibody treatment tests

Yahoo Finance's Anjalee Khemlani reports on the latest in developments treatment for the coronavirus.

Other stocks mentioned: GSK
The Motley Fool - 4 months ago

The treatment to prevent hospitalization from COVID-19 could be available in the first half of 2021.

Other stocks mentioned: GSK
Zacks Investment Research - 4 months ago

Market Waits for Major Economic Data This Week.

Other stocks mentioned: ABT, GSK
CNBC Television - 4 months ago

GSK chief scientist and Vir CEO on clinical trial for Covid-19 antibody drug

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage Covid-19 patients, entering the race to find a winner in a promising class of anti...

Other stocks mentioned: GSK
CNBC Television - 4 months ago

GlaxoSmithKline and Vir start phase 2/3 study for Covid-19 antibody drug

Vir Biotechnology and GlaxoSmithKline announced Monday that the first patient was dosed last week in a phase 2/3 study on an antibody drug meant for the early treatment of COVID-19 in patients...

Other stocks mentioned: GSK
Market Watch - 4 months ago

Shares of Vir Biotechnology Inc. VIR, +1.31% gained 9.2% in premarket trading on Monday when the company and GlaxoSmithKline GSK, -0.37% said they had begun dosing patients in the Phase 2/3 cl...

Other stocks mentioned: GSK
CNBC - 4 months ago

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage Covid-19 patients.

Other stocks mentioned: GSK
Reuters - 4 months ago

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of anti...

Other stocks mentioned: GSK
GlobeNewsWire - 4 months ago

SAN FRANCISCO and LONDON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced that the first patient was dosed last week...

Other stocks mentioned: GSK
GlobeNewsWire - 5 months ago

SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, to...

Zacks Investment Research - 5 months ago

Let us take a look at two small biotech companies, VIR and AUPH, which are gearing up for their earnings release.

Other stocks mentioned: AUPH
GlobeNewsWire - 5 months ago

SAN FRANCISCO, July 28, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, to...

GlobeNewsWire - 6 months ago

SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Elliott Sigal, M.D., Ph.D., to its board of directors. Dr. Sigal for...

GlobeNewsWire - 6 months ago

SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, to...

About VIR

Vir Biotechnology, a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Bios... [Read more...]

Industry
Biotechnology
IPO Date
Oct 11, 2019
CEO
Dr. George A. Scangos
Employees
297
Stock Exchange
NASDAQ
Ticker Symbol
VIR
Full Company Profile

Financial Performance

In 2019, VIR's revenue was $8.09 million, a decrease of -24.16% compared to the previous year's $10.67 million. Losses were -$174.68 million, 50.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for VIR stock is "Buy." The 12-month stock price forecast is 54.86, which is an increase of 30.15% from the latest price.

Price Target
$54.86
(30.15% upside)
Analyst Consensus: Buy